Brief: NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial

Neurosense Therapeutics

06/11/2023 13:38

Nov 6 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE COMPLETES DOSING OF LAST PATIENT IN THE
DOUBLE-BLIND
SEGMENT OF PHASE 2B ALS TRIAL: TOPLINE CLINICAL EFFICACY RESULTS
EXPECTED DECEMBER 2023
    * NEUROSENSE THERAPEUTICS LTD: CLINICAL EFFICACY RESULTS AND
SAFETY RESULTS EXPECTED IN DECEMBER 2023
    * NEUROSENSE THERAPEUTICS LTD- BIOGEN COLLABORATION
BIOMARKER
RESULTS EXPECTED Q1 2024
    * NEUROSENSE THERAPEUTICS LTD- PRIMARY BIOMARKER ENDPOINTS
TO BE
REPORTED H1 2024

Source text for Eikon:  ID:nPn56zCCpa 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))